BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

ALC upcoming catalysts

Alcon Research: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 1 FDA event(s). Subscribe to ALC (.ics).

Drugs: Apraclonidine Ophthalmic, 0.125% Unit Preservative Free

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-02 est.P3Alcon Research ALCNCT07531043 Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in AdultsOcular Hyperemiarecruiting230

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-10-16FDA approvalapprovedALCON LABS INC ALCBRYTLYApproved 2026-10-16: BRYTLY (NDA220341 ORIG1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3Alcon Research ALCNCT07578363 An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in AdultsOcular Hyperemiarecruiting178
2026-04-06P3Alcon Research ALCNCT07082816 Reformulated PG324 Ophthalmic Solution for Intraocular Pressure ReductionOcular Hypertension; Open Angle Glaucomacompleted489

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.